Skip to main content
. 2022 Jun 3;39(10):2405–2419. doi: 10.1007/s11095-022-03305-y

Fig. 7.

Fig. 7

In vitro digestion studies of Tol IL in MCF-2 (Type IIIB) formulation. Increasing the proportion of surfactant (Kolliphor® EL) in the formulation, improved formulation dispersion (-15 – 0 min; grey section), and drug solubilisation during digestion (0 – 60 min). Tol Dec and Tol Dec Ala, were loaded into the Type IIIB formulation, at mol equivalent concentrations to that employed in the lipolysis studies with the Type IIIA formulation (MCF-1). (mean ± SD; n = 3)